hypovitaminosis d3 in ulcerative colitis patients receiving nfiliximab and the effect of vitamin d3 replacement on remission and body composition analysis / (Record no. 169787)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06228namaa22004331i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20250223033355.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241228s2023 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.328 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615.328 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.11.33.M.Sc.2023.Ha.H |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Hadeer Hosny Salem Mahdy, |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | hypovitaminosis d3 in ulcerative colitis patients receiving nfiliximab and the effect of vitamin d3 replacement on remission and body composition analysis / |
| Statement of responsibility, etc. | by Hadeer Hosny Salem Mahdy ; Supervision of Prof. Dr. Samar Kamal Ahmed Darweesh, Prof. Dr. Hanan Hassan Fouad, Prof. Dr. Kamal-Eldin EL-Atrebi. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | /دارسة أثر فیتامین د لعلاج القولون التقرحى على تحسن المرضى وعلى تكون أجسامهم |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 150 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc.)-Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 115-151. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Introduction: Ulcerative Colitis is One of inflammatory bowel diseases characterized by recurring episodes of inflammation limited to the mucosal layer of the colon involving only colon. Vitamin D has numerous effects on cells within the immune system. Then vitamin D may have anti-inflammatory effect in patients of ulcerative colitis. Body composition analysis divides the body into compartments of fat and fat free-mass (lean mass).Vitamin D level has a direct effect on body composition(lean body mass).We aimed to detect effect of vitamin D as an adjuvant therapy in remission of ulcerative colitis recieving infiliximab and studing its effect on body composition analysis. <br/>Patients and method: A 45 Adult patients having ulcerative colitis, diagnosed by colonoscopy and biopsy with histological examination, with hypovitaminosis D3 were followed-up after 4 months of receiving vitamin D replacement as an adjuvant therapy to infiliximab. <br/>Results: After 4 months of VD as an adjuvant therapy with anti TNF (Infliximab) there was significant increase in serum VD from a mean 16.85 (range 9-20) ng/mL to 35.81 (range 17-89) ng/mL (p<0.001) in current enrolled patients. There was a significant improvement in disease activity by decreasing Mayo score from a mean 6.16 (range 3-11) to 2.81 (range 0-6) (p=0.001) after VD replacement therapy. Even with a significant improvement in VD levels and GIT manifestation of UC, there was no significant improvement in any parameters of body composition (body fat, water, muscle mass, bone, BMR or AMR; p>0.05). <br/>Conclusion: The current study revealed that the intervention with oral VD supplementation is safe and well tolerated. It has been more challenging to identify the advantages of restoring VD levels in clinical disease progression, but more studies are beginning to reveal benefits. Aside from the well-recognized skeletal effects, there is growing evidence for IBD disease outcome benefits from the normalization of VD serum levels in people with IBD. Benefits include: reduced risk of surgery, reduction in inflammatory markers (platelets and CRP), reduction in the UC activities (Mayo score) and improved response to anti-TNF alpha treatment (Infliximab). These benefits warrant attention to the VD status of people with IBD. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | عد نقص فیتامین د مش لة شائعة في المرضى الذین عانون من التهاب القولون التقرحي والذ صل اح انا الي ٥٤ -٠٥٪. <br/>لا ت ازل فوائد م ملات فیتامین د لمرضى التهاب القولون التقرحي غیر واضحة ، وتحسین مستو فیتامین د قد ساعد في منع ظهور التهاب القولون التقرحي و ذلك التخفیف من شدة المرض. <br/>الهدف من الدارسة: <br/>ان الهدف من الد ارسة الحال ة هو اكتشاف فعال ة استخدام فیتامین د علاج مساعد على تكو?ن الجسم وفي علاج التهاب القولون التقرحي. <br/>المرضى وطرق الدارسة: <br/>اشتملت الد ارسة الحال ة على ٤٥ مر?ضًاB الغًا تم تشخ صهمB التهاب القولون التقرحي عن طر C?تنظیر القولون والخزعة مع الفحص النسیجي. وهم من المترددین علي وحدة أم ارض الكبد وطب المناط Cالحارة التاBعة للمعهد الوطني لأم ارض الكبد وع ادة المرضى الخارجیین المصابین بنقص فیتامین د في وقت بدأ من أكتوHر ٢٠١٩ وتم متاBعتهم لمدة ٤ أشهر من تلقي فیتامین د علاج مساعد لإنفیل س ماب. ان هناك سBعة من المرضى لم نتم ن من متاBعتهم خلال فترة المتاBعة. لذلك ، تم فحص ٣٨ مر?ضا في الز?ارة الثان ة. <br/>معاییر الانضمام للدارسة: <br/>• المرضى الBالغون الذین تز?د أعمارهم عن ١٨ عامًا والذین عانون من التهاب القولون التقرحي المرت PBبنقص فیتامین د. <br/>• التهاب القولون التقرحي ذو النشا Rالخفیف إلى متوسP تم تقی مه بواسطة مع ار مایو. <br/> |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Vitamins |
| Source of heading or term | qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Ulcerative Colitis |
| -- | Infiliximab |
| -- | Vitamin |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Samar Kamal Ahmed Darweesh |
| Relator term | Reviewer. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hanan Hassan Fouad |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kamal-Eldin EL-Atrebi |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2023 |
| Supervisory body | Samar Kamal Ahmed Darweesh |
| -- | Hanan Hassan Fouad |
| -- | Kamal-Eldin EL-Atrebi Diseases and Endemic Hepato-Gastroenterology Diseases |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Infectous |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 28.12.2024 | 90083 | Cai01.11.33.M.Sc.2023.Ha.H | 01010110090083000 | 28.12.2024 | 28.12.2024 | Thesis |